Clinical Trials Logo

Overweight clinical trials

View clinical trials related to Overweight.

Filter by:

NCT ID: NCT06458634 Completed - Clinical trials for Adolescent Overweight

Weight Variation on Cop

Start date: November 1, 2023
Phase:
Study type: Observational

This study will be conducted to investigate the impact of variant weights in adolescents during unperturbed standing conditions.

NCT ID: NCT06455878 Not yet recruiting - Heart Failure Clinical Trials

Mobile Applet for Weight Management in Obese Heart Failure Patients

IDEAL-HF
Start date: June 6, 2024
Phase: N/A
Study type: Interventional

The objective of this clinical trial is to investigate the effect of weight reduction through a diet management application and an intelligent weight scale on a composite cardiovascular endpoint in obese patients with heart failure. The main questions are: Does the use of a diet management APP and intelligent weight scale reduce 1-year all-cause mortality, heart failure hospitalization, and first heart failure hospital stay? Does the use of a diet management APP and intelligent weight scale improve the outcomes of assessment of heart failure frailty and quality of life for heart failure? Researchers will compare using the fully functional diet management app and intelligent weight scale to using the limitedly functional app and intelligent weight scale to see if the app works to improve heart failure conditions. Participants will: Use the diet management app at every meal and the intelligent weight scale every day for 12 months, and visit the clinic at 12 months for checkups.

NCT ID: NCT06452511 Not yet recruiting - PCOS Clinical Trials

Comparing the Effect of Metformin vs. Pep2dia as an Adjunct to Letrozole on Ovulation Induction and Pregnancy Outcomes in Overweight Women With PCOS

Start date: July 1, 2024
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to compare the effects of Metformin versus Pep2dia as adjunct treatments to Letrozole on ovulation induction and pregnancy outcomes in overweight women with polycystic ovary syndrome (PCOS). The main questions it aims to answer are: Does Metformin improve ovulation rates more effectively than Pep2dia when used alongside Letrozole? Does Pep2dia enhance pregnancy outcomes compared to Metformin in this patient population? Participants will: Receive either Metformin or Pep2dia in addition to Letrozole. Undergo regular monitoring for ovulation and pregnancy outcomes. Researchers will compare the Metformin group to the Pep2dia group to see if there is a significant difference in ovulation and pregnancy rates between the two treatments.

NCT ID: NCT06450847 Not yet recruiting - Obesity Clinical Trials

Effect of Soleus Muscle Push Ups on Oxidative Stress and Inflammatory Markers, Soleus Endurance, and Adipocytokines Between Type 2 Diabetic, Overweight/Obese and Normal Weight Individuals.

Start date: June 2024
Phase: N/A
Study type: Interventional

The study aims to investigate the impact of Soleus Push Ups (SPU) on Soleus Muscle endurance, Oxidative Stress Markers, Inflammatory markers and Adipocytokines among people in the United Arab Emirates. This will be a pre-post intervention study with participants divided into three groups: Lean normal metabolic profile, metabolically healthy overweight/obese, and patients with Type 2 Diabetes Mellitus. Assessment of anthropometry and body composition, Soleus Muscle Endurance, blood tests for Inflammatory Markers, Oxidative Stress Markers, and Adipocytokines will be conducted pre and post-intervention.

NCT ID: NCT06448858 Not yet recruiting - Mineral Deficiency Clinical Trials

Minerals Status in Relation to Overweight and Obese Adolescent

Start date: June 2024
Phase:
Study type: Observational [Patient Registry]

Evaluation of the concentration of serum Mn, Se, iron, Cu & Zn levels in obese and overweight adolescents, Correlate the body composition parameters with these minerals' concentration, Study the association between the metabolic risk factors and the disturbance in minerals levels in these patients.

NCT ID: NCT06445296 Recruiting - Clinical trials for Overweight or Obesity

Postprandial Effects of Animal Versus Plant-Based Protein

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

Shifting away from diets high in animal products towards more plant predominant diets is recommended by many health organizations to both reduce the negative environmental impacts of animal agriculture and to improve health outcomes. As a result, a number of plant-based meat alternatives such as Beyond Meat have been formulated to promote increased plant consumption. However, evidence is limited on the impact of newer plant-based meat alternatives on common cardiometabolic risk factors. The investigators aim to compare the acute metabolic, gastrointestinal, and inflammatory effects of a plant-based meat alternative (i.e., Beyond Meat) versus a comparable beef product within the context of high-fat, "Western-style" meal (i.e., eggs, meat, refined bread product). The investigators will also examine whether these responses differ based on whether individuals have a normal-weight or have overweight/obesity.

NCT ID: NCT06445075 Recruiting - Clinical trials for Overweight and Obesity

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

EMBRAZE
Start date: May 21, 2024
Phase: Phase 2
Study type: Interventional

A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 agonist therapy in subjects with overweight or obesity

NCT ID: NCT06444464 Not yet recruiting - Clinical trials for Overweight and Obesity

The BEE-Power Study (Boosting Exercise for Excellent Pediatric Blood Pressure)

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to compare two types of exercises, isometric exercise (like squats and planks) and aerobic exercise (such as running), to see which one is more effective at improving blood pressure in teenagers aged 13 to 17.5 years. The main question the study aims to answer is: - Do the effects of one session of isometric exercise on the blood pressure of adolescents compare to the effects of one session of aerobic exercise? Adolescents diagnosed with high blood pressure may qualify for this study. Participants will be randomly assigned to either a single session of isometric exercise or a single session of aerobic exercise. - Participants will attend 3 study visits in total. - Study visits should be completed within 4 weeks of enrollment. - At the initial visit, samples (example: blood) will be collected and body measurements will be taken. - Participants will be asked to answer questionnaires (diet, growth, and others) - At visit 2, participants will have their blood pressure measured using a 24 hour blood pressure monitor. - At visit 3, participants will participate in a single session of either aerobic or isometric exercise. They will wear a 24-hour blood pressure monitor immediately after the exercise session.

NCT ID: NCT06440980 Not yet recruiting - Healthy Clinical Trials

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

Start date: June 24, 2024
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated. The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each, including the screening period.

NCT ID: NCT06440213 Recruiting - Overweight Clinical Trials

A Study to Determine the Safety and Tolerability of a Range of Doses of PeptiControl in Pre-diabetic Individuals

Start date: May 20, 2024
Phase: N/A
Study type: Interventional

A randomised, double blind, placebo controlled parallel study to examine the effects of a dose range of PeptiControl, a plant-based ingredient, in pre-diabetic males and females.